## AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

## LISTING OF CLAIMS:

 $\mbox{1. (original) A clopidogrel salt having the following} \label{eq:clopidogrel}$  formula (I)

wherein R is a straight or branched  $C_1 - C_{10}$  alkyl group.

- 2. (currently amended) [[A]] <u>The</u> clopidogrel salt as claimed in claim 1, wherein R is a straight or branched  $C_1\text{-}C_6$  alkyl group.
- 3. (currently amended) [[A]] <u>The</u> clopidogrel <u>salt</u> as claimed in claim 1, which is:

clopidogrel-methyl sulfate; clopidogrel-ethyl sulfate; clopidogrel-propyl sulfate; clopidogrel-isopropyl sulfate; clopidogrel-butyl sulfate; clopidogrel-sec-butyl sulfate; clopidogrel-isobutyl sulfate or clopidogrel-tert-butyl sulfate.

4. (original) A pharmaceutical composition comprising as active ingredient a clopidogrel salt, as claimed in claim 1, and a pharmaceutically acceptable excipient and/or carrier.

- 5. (currently amended) A process for the purification of clopidogrel or clopidogrel hemisulfate, comprising respectively:
- a)  $\frac{\text{reaction of }}{\text{reacting }}$  clopidogrel with concentrated sulfuric acid in a  $C_1-C_{10}$  alkanol; or
- b)  $\frac{\text{reaction of }}{\text{reacting}}$  clopidogrel hemisulfate with a  $C_1\text{-}C_{10}$  alkanol; or
- c) salification of clopidogrel with an alkylsulfuric acid of formula

 $R-O-S(O)_3H$ , wherein R is as claimed in claim 1; and conversion of the resulting clopidogrel  $C_1-C_{10}$  alkyl sulfate salt to clopidogrel (base) and, if desired optionally, salification to clopidogrel hemisulfate.

- 6. (currently amended) Highly pure A clopidogrel and clopidogrel hemisulfate as having purity approximately equal to or higher than 99% and obtainable according to the purification process as claimed in claim 5.
- 7. (original) Crystalline form of a clopidogrel salt as claimed in claim 1.